Medicinal Products

Comirnaty, cjepivo protiv COVID-19 (mRNA, modificirani nukleozid)

The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.

Name Comirnaty, cjepivo protiv COVID-19 (mRNA, modificirani nukleozid)
Active Substance jednolančana glasnička RNA (mRNA) s kapom na 5'kraju, koja kodira protein šiljka (S) virusa SARS-CoV-2, dobivena pomoću in vitro transkripcije iz odgovarajućih predložaka DNA, bez korištenja stanica
Prescription na recept
Type of prescription neponovljivi recept
Distribution u ljekarni
ATC Code J07BN01
Medicinal product marketed in the Croatia Da
Summary of product characteristics (SmPC), labelling and package leaflet (PL) download
Link to the European Medicines Agency's (EMA) product information download
Link to the European Commission's (EC) decisions download

Packaging

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o ažuriranju roka valjanosti za cjepivo protiv bolesti COVID-19 Comirnaty - veljača 2022. 07.02.2022 BioNTech Manufacturing/Pfizer Croatia d.o.o.
Pismo zdravstvenim radnicima o ažuriranju roka valjanosti za cjepivo protiv bolesti COVID-19 Comirnaty 29.09.2021 BioNTech Manufacturing/Pfizer Croatia d.o.o.
Pismo zdravstvenim radnicima o riziku od miokarditisa i perikarditisa za mRNA cjepiva protiv bolesti COVID-19 Comirnaty i Spikevax 19.07.2021 BioNTech Manufacturing/Pfizer Croatia d.o.o., Moderna Biotech Spain, S.L.
Back